Use these links to rapidly review the document
TABLE OF CONTENTS
Table of Contents
This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not
complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting offers to buy these securities
in any jurisdiction where the offer or sale is not permitted.
Filed pursuant to Rule 424(b)(5)
Registration No.: 333-201346
SUBJECT TO COMPLETION, DATED APRIL 30, 2015
PRELIMINARY PROSPECTUS SUPPLEMENT
(to Prospectus dated January 15, 2015)
Shares
Common Stock
We are offering shares of our common stock pursuant to this prospectus supplement and the
accompanying prospectus.
Our
common stock is traded on the NASDAQ Global Market under the symbol "TLOG". On April 29, 2015, the last reported sale price of our common stock on the NASDAQ Global Market was
$4.15 per share.
We are an "emerging growth company" as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company
reporting requirements. Investing in our common stock involves a high degree of risk. Before buying any shares, you should review carefully the risks and uncertainties described under the heading
"Risk Factors" beginning on page S-8 of this prospectus supplement, on page 3 of the accompanying prospectus and under similar headings in the other documents that are incorporated by
reference into this prospectus supplement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PER SHARE
|
|
TOTAL
|
|
|
|
Public offering price |
|
$ |
|
|
$ |
|
|
|
|
Underwriting discount(1) |
|
$ |
|
|
$ |
|
|
|
|
Offering proceeds to TetraLogic Pharmaceuticals Corporation before expenses |
|
$ |
|
|
$ |
|
|
|
|
- (1)
- See
"Underwriting" for additional information regarding underwriting compensation.
The Securities and Exchange Commission or any state securities commission has not approved or disapproved of these securities or determined if this prospectus
supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
We
have granted the underwriters an option for a period of 30 days to purchase up to an additional shares of our common stock. If the underwriters exercise
the option in full, the total public offering
price will be $ , the total underwriting discount will be $ , and our total proceeds, before expenses, will
be $ .
Delivery
of the common stock is expected to be made on or about May , 2015.
The date of this prospectus is May , 2015
Table of Contents
TABLE OF CONTENTS
i
Table of Contents
ABOUT THIS PROSPECTUS SUPPLEMENT
This prospectus supplement and the accompanying prospectus are part of a "shelf" registration statement on Form S-3 (File
No. 333-201346) that we initially filed with the Securities and Exchange Commission, or SEC, on January 2, 2015, and that was declared effective by the SEC on January 15, 2015.
This document is in two parts. The first part is this prospectus supplement which describes the terms of this offering of our common stock and adds to and updates the information contained in the
accompanying prospectus. The second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we
are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the
accompanying prospectus, you should rely on the information in this prospectus supplement.
This
prospectus supplement and the accompanying prospectus relate to the offering of shares of our common stock. Before buying any of the shares of common stock offered hereby, we urge
you to read carefully this prospectus supplement and the accompanying prospectus, together with the information incorporated herein by reference as described below under the heading "Incorporation of
Certain
Information by Reference." This prospectus supplement contains information about the common stock offered hereby and may add to, update or change information in the accompanying prospectus.
You
should rely only on the information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus. We have not, and the underwriters
have not, authorized anyone to provide you with different or additional information.
We
are not making offers to sell or solicitations to buy our common stock in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer
or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information in this prospectus supplement and the
accompanying prospectus is accurate only as of the date on the front of the respective document and that any information that we have incorporated by reference is accurate only as of the date of the
document incorporated by reference, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or the time of any sale of a security.
This
prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be
filed or will be incorporated herein by reference as exhibits to the registration statement, and you may obtain copies of those documents as described below under the section entitled "Where You Can
Find More Information."
We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were
made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a
representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs.
This
prospectus supplement and the accompanying prospectus contain and incorporate by reference market data and industry statistics and forecasts that are based on independent industry
publications and other publicly-available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not
independently
S-1
Table of Contents
verified
this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement, accompanying prospectus or the documents
incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the headings "Risk Factors" in
this prospectus supplement and the accompanying prospectus, and under similar headings in the other documents that are incorporated herein by reference. Accordingly, investors should not place undue
reliance on this information.
This
prospectus supplement and the accompanying prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other
companies. All trademarks, service marks and trade names included or incorporated by reference herein are the property of their respective owners.
Unless
the context otherwise requires, in this prospectus supplement the "Company," "we," "us," "our" and similar names refer to TetraLogic Pharmaceuticals Corporation and its
consolidated subsidiaries.
S-2
Table of Contents
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights selected information contained elsewhere in, or incorporated by reference into, this
prospectus supplement or the accompanying prospectus, and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire
prospectus supplement and the accompanying prospectus, including the risks of
investing in our securities discussed under the headings "Risk Factors" on page S-8 of this prospectus supplement, page 3 of the accompanying prospectus, and under similar headings in
the other documents that are incorporated by reference herein.
We
are a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. We currently have two
clinical-stage product candidates in development: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester, or SHAPE.
Birinapant
is a novel small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases, or SMAC-mimetic, which leads to apoptosis, or cell-death, in damaged cells. We
have treated over 300 oncology subjects in clinical trials with birinapant, and in non-randomized clinical trials to date, we have seen activity in subjects with (i) higher risk myelodysplastic
syndromes, or MDS, where we have observed complete bone marrow responses with birinapant administered with azacitidine (Vidaza®); (ii) end-stage acute myeloid leukemia, where
birinapant was administered as a single-agent and subjects who have previously relapsed or were refractory to standard therapy experienced declines in blast counts; (iii) ovarian cancer, where
birinapant was administered with conatumumab (AMG 655), we have observed disease stabilization and a partial response, or PR, in women who previously relapsed or were refractory to standard therapy;
and (iv) colorectal cancer, where birinapant was administered with irinotecan, we have observed evidence of anti-tumor activity or prolonged disease stabilization in subjects who have
progressed after multiple prior therapies, including irinotecan.
Most
recently, we have generated pre-clinical data indicating that birinapant induces apoptosis in-vivo in mouse hepatocytes infected with human hepatitis B virus, or HBV. In a mouse
model, we have seen clearance of HBV surface antigen, or HBsAg, and the appearance of antibodies directed against HBsAg, a clinical finding considered equivalent to a functional cure. We have also
seen activity of birinapant in other infectious disease models, including human mononuclear cells infected with human immunodeficiency virus, or HIV, in-vitro, and in-vivo in mouse models of
Mycobacterium tuberculosis and legionella pneumophila.
We
are currently conducting the following three clinical programs with birinapant:
-
- In June 2014, we commenced a randomized, double-blind placebo-controlled Phase 2 clinical trial of birinapant administered with
azacitidine in subjects with previously untreated, higher risk MDS. Interim data is expected in 2015. This clinical trial follows our Phase 1b/2a open-label clinical trial of birinapant
administered with azacitidine.
-
- We are continuing enrollment in a Phase 1/2 open-label, non-randomized clinical trial of birinapant administered with
conatumumab in third-line ovarian cancer. In December 2014, this clinical trial proceeded into a Phase 2a expansion based upon data in the Phase 1 portion of the clinical trial.
Phase 2a clinical trial data is expected in 2015.
-
- We recently initiated a randomized, placebo-controlled, multiple ascending dose Phase 1 clinical trial in subjects with chronic
HBV currently taking entecavir or tenofovir. Data is expected in 2015.
We
discovered birinapant, and its composition of matter patent in the U.S. extends until at least 2030. We have retained worldwide development and commercialization rights for all
indications.
S-3
Table of Contents
SHAPE,
our second clinical-stage product candidate, is a histone deacetylase, or HDAC, inhibitor that we are developing for topical use for the treatment of early-stage cutaneous T-cell
lymphoma, or CTCL. HDAC is a validated cancer target, and HDAC inhibitors, or HDACi, are a proven class of anti-cancer drugs for CTCL. SHAPE is a novel therapeutic, designed to maximize HDAC
inhibition locally in the skin with limited systemic exposure, and it has characteristics that could allow its topical use over large body surface areas with minimal systemic absorption. By
potentially avoiding toxicities typical of systemically-administered HDACi's, SHAPE may provide a more favorable safety profile than current HDACi's delivered orally or intravenously. SHAPE has been
evaluated in a randomized, placebo-controlled dose escalation Phase 1 clinical trial in early-stage CTCL. SHAPE was well-tolerated, and it demonstrated evidence of clinical activity with PRs
observed in certain subjects after 28 days of application. We commenced a randomized Phase 2 clinical trial of SHAPE in subjects with early-stage CTCL in December 2014, which will assess
clinical activity after six months of application. Data for this clinical trial is expected in 2015.
SHAPE's
composition of matter patent in the U.S. extends until at least 2028. In addition, SHAPE has been granted U.S. orphan drug designation for CTCL. We have acquired worldwide
development and commercialization rights to SHAPE for all indications.
You
can get more information regarding our business and industry by reading our most recent Annual Report on Form 10-K and the other reports we file with the SEC. See "Where You
Can Find More Information" and "Incorporation of Certain Documents by Reference."
Corporate Information
Our principal executive offices are located at 343 Phoenixville Pike, Malvern, Pennsylvania 19355, and our telephone number is
(610) 889-9900. Our website address is www.tlog.com. The content contained in, or that can be accessed through, our website is not part of this prospectus supplement or the accompanying
prospectus. We make available free of charge on our website our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically
file such material with, or furnish such material to, the SEC.
Implications of Being an Emerging Growth Company
We are an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities
Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of exemptions from various disclosure and reporting requirements that
are applicable to other public companies that are not "emerging growth companies" including, but not limited to:
-
- not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, or
the Sarbanes-Oxley Act;
-
- being permitted to present only two years of audited financial statements and only two years of related Management's Discussion and
Analysis of Financial Condition and Results of Operations, in each case, instead of three years;
-
- being permitted to present the same number of years of selected financial data as the years of audited financial statements presented,
instead of five years;
-
- reduced disclosure obligations regarding executive compensation, including no Compensation Disclosure and Analysis;
-
- not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
mandatory audit firm rotation or a supplement to the
S-4
Table of Contents
We
may choose to take advantage of some or all of the available exemptions. We have taken advantage of some of the reduced reporting burdens in this prospectus. Accordingly, the scope of
the information contained herein may be different than the scope of the information you receive from other public companies in which you hold stock. We do not know if some investors will find our
shares less attractive as a result of our utilization of these or other exemptions. The result may be a less active trading market for our shares and our share price may be more volatile.
In
addition, Section 107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B)
of the Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same
new or revised accounting standards as other public companies that are not emerging growth companies.
We
will remain an "emerging growth company" until the earliest of (a) the last day of the first fiscal year in which our annual gross revenues exceed $1.0 billion;
(b) the date that we become a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the
market value of our shares that are held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; (c) the date on which we
have issued more than $1.0 billion in nonconvertible debt during the preceding three-year period; and (d) the last day of our fiscal year containing the fifth anniversary of the date on
which shares of our common stock become publicly traded in the United States.
S-5
Table of Contents
THE OFFERING
|
|
|
Common stock offered by us pursuant to this prospectus supplement |
|
Up to shares. |
Common stock estimated to be outstanding immediately after this offering |
|
shares
(or shares if the underwriters exercise in full their option to purchase additional shares). |
Option to purchase additional shares |
|
We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to
purchase up to additional shares. |
Use of Proceeds |
|
We currently intend to use the net proceeds from the sale of the shares of common stock offered by us hereunder for general
corporate purposes, including working capital, continued development of our product candidate pipeline, acquisitions and other business opportunities. See "Use of Proceeds" on page S-12 of this prospectus supplement. |
Risk Factors |
|
An investment in our common stock involves a high degree of risk. See the information contained in or incorporated by
reference under "Risk Factors" on page S-8 of this prospectus supplement, page 3 of the accompanying prospectus, and under similar headings in the other documents that are incorporated by reference herein, as well as the other information
included in or incorporated by reference in this prospectus supplement and the accompanying prospectus. |
NASDAQ Global Market Symbol |
|
Our common stock is quoted and traded on NASDAQ Global Market under the symbol "TLOG." |
The
number of shares of our common stock to be outstanding immediately after this offering is based on 22,334,901 shares of common stock outstanding as of December 31, 2014.
Unless specifically stated otherwise, the information in this prospectus supplement is as of December 31, 2014 and excludes:
-
- 3,277,308 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2014, at a
weighted average exercise price of $5.53 per share, of which options to purchase 1,690,999 shares of our common stock were then exercisable;
-
- 21,786 shares of our common stock issuable upon the exercise of warrants issued in 2006, and which remained outstanding as of
December 31, 2014, each with an exercise price of $7.65 per share, 10,893 of which will be exercisable until March 30, 2016 and 10,893 of which will be exercisable until May 5,
2016;
-
- 1,961 shares of our common stock issuable upon the exercise of warrants issued in 2007, and which remained outstanding as of
December 31, 2014, each with an exercise price of $7.65 per share, all of which will be exercisable until May 2, 2017;
-
- 52,815 shares of our common stock issuable upon the exercise of warrants issued in 2009 and 2010, and which remained outstanding as of
December 31, 2014, each with an exercise price of
S-6
Table of Contents
$0.85
per share, 24,007 of which will be exercisable until November 25, 2019 and 28,808 of which will be exercisable until March 10, 2020;
-
- an aggregate of 2,942,629 shares of our common stock reserved for future grants under our 2004 Equity Incentive Plan, as amended, and
our Amended and Restated 2013 Equity Incentive Plan as of December 31, 2014;
-
- 524,304 shares of our common stock issued in exchange for an aggregate principal amount of notes of $3,250,000 under exchange
agreements dated March 3, 2015;
-
- 7,137,031 shares of our common stock that are issuable upon conversion of our aggregate principal amount of notes of $43,750,000 plus
interest-make-whole payments, as of the date hereof; and
-
- 450,000 shares of restricted common stock granted to executive officers, and options to purchase 705,000 shares of our common stock at
$5.25 per share granted to executive officers, directors, and employees, effective January 28, 2015.
If
the underwriters' option to purchase additional shares is exercised in full, we will issue and sell up to an additional shares of our common stock and will
have
shares outstanding after this offering.
Except
as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase additional shares of common stock.
S-7
Table of Contents
RISK FACTORS
Investing in shares of our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you
should consider carefully the risks and uncertainties described in the section entitled "Risk Factors" contained in this prospectus supplement, in the accompanying prospectus, in our most recent
Annual Report on Form 10-K and in any documents incorporated by reference herein. The risks described in these documents are not the only ones we face, but those that we consider to be
material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. If any of these risks
actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss
of all or part of your investment. Further, past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends
in future periods.
Risks Related to this Offering
We have broad discretion in the use of the net proceeds of this offering and, despite our efforts,
we may use the proceeds in a manner that does not improve our operating results or increase the value of your investment.
We currently anticipate that the net proceeds from the sale of our common stock will be used for general corporate purposes, including
working capital, continued development of our product candidate pipeline, acquisitions and other business opportunities. However, we have not determined the specific allocation of the net proceeds
among these potential uses. Our management will have broad discretion over the use and investment of the net proceeds of this offering, and, accordingly, investors in this offering will need to rely
upon the judgment of our management with respect to the use of proceeds, with only limited information concerning our specific intentions. These proceeds could be applied in ways that do not improve
our operating results or increase the value of your investment. Please see the section entitled "Use of Proceeds" on page S-12 of this prospectus supplement for further information.
If you purchase the common stock sold in this offering, you will experience immediate dilution as a
result of this offering and future equity issuances.
Because the price per share of our common stock being offered is higher than the book value per share of our common stock, you will
suffer immediate substantial dilution in the net tangible book value of the common stock you purchase in this offering. See the section entitled "Dilution" on page S-13 of this prospectus
supplement for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.
The
issuance of additional shares of our common stock in future offerings could be dilutive to stockholders if they do not invest in future offerings. Holders of shares of our common
stock have no preemptive rights that entitle them to purchase their pro rata share of any offering of shares of any class or series. Moreover, to the extent that we issue options or warrants to
purchase, or securities convertible into or exchangeable for, shares of our common stock in the future and those options, warrants or other securities are exercised, converted or exchanged,
stockholders may experience further dilution.
Our ability to use our net operating loss carryforwards and certain other tax attributes to offset
future taxable income may be limited.
Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an
"ownership change," its ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change taxable income may be
S-8
Table of Contents
limited.
Generally, an ownership change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect "five percent shareholders" increases by more than
50 percentage points over their lowest ownership percentage at any time during the applicable testing period (typically, three years). We believe we have experienced an ownership change in the
past, and may experience ownership changes in the future as a result of future transactions in our stock, some of which may be outside our control. As a result, our ability to use our pre-change net
operating loss carryforwards, or other pre-change tax attributes, to offset any future U.S. federal taxable income may be subject to significant limitations.
S-9
Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein contain
forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this prospectus supplement, the accompanying
prospectus and the documents incorporated by reference herein and therein regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and
objectives of management are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "potential," "intend," "may," "plan," "predict," "project," "will," "should," "would"
and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The
forward-looking statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein include, among other things,
statements about:
-
- our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;
-
- the success and timing of our pre-clinical studies and clinical trials;
-
- the difficulties with increasing the size and complexity of our organization to assist with the expansion of our operations;
-
- the potential that results of pre-clinical studies and clinical trials indicate birinapant or SHAPE is unsafe or ineffective;
-
- our exposure to business disruptions;
-
- our dependence on third parties in the conduct of our pre-clinical studies and clinical trials;
-
- the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates, and the
labeling under any approval we may obtain;
-
- our plans and ability to develop and commercialize our product candidates;
-
- our ability to acquire or license additional product candidates;
-
- our failure to recruit or retain key scientific or management personnel or to retain our executive officers;
-
- the size and growth of the potential markets for our product candidates, market acceptance of our product candidates and our ability
to serve those markets;
-
- legal and regulatory developments in the U.S. and foreign countries;
-
- our ability to limit our exposure to product liability lawsuits;
-
- our exposure to scrutiny and increased expenses as a result of being a public company;
-
- the rate and degree of market acceptance of our product candidates;
-
- obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;
-
- the successful development of our commercialization capabilities, including sales and marketing capabilities;
-
- recently enacted and future legislation regarding the healthcare system;
-
- the success of competing therapies and products that are or become available;
S-10
Table of Contents
-
- our ability to acquire products or product candidates with acceptable economics;
-
- our ability to raise additional capital;
-
- our ability to pay existing indebtedness;
-
- the decrease in the market price of our common stock from the issuance of additional shares of or instruments convertible into common
stock;
-
- the effect on our financial results from the conversion of our convertible notes;
-
- the dilution of existing stockholders from the conversion of our convertible notes;
-
- our use of proceeds from this offering;
-
- the dilution of our stockholders' ownership interests as a result of this offering and future equity issuances; and
-
- our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income.
Birinapant
and SHAPE are investigational drugs undergoing clinical development and have not been approved by the U.S. Food and Drug Administration or submitted to the FDA for approval.
Birinapant and SHAPE have not been, nor may ever be, approved by any regulatory agency or marketed anywhere in the world. Statements contained in this prospectus supplement or the accompanying
prospectus should not be deemed to be promotional.
We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary
statements included in this prospectus supplement, particularly under "Risk Factors," that we believe could cause actual results or events to differ materially from the forward-looking statements that
we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments we may make.
You
should read this prospectus supplement, the accompanying prospectus and the documents that we incorporate by reference herein and therein completely and with the understanding that
our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements.
Except
as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. You should not
assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully
consider the risk factors discussed and incorporated by reference in this prospectus supplement and the accompanying prospectus and in the registration statement of which this prospectus supplement
and the accompanying prospectus are a part.
S-11
Table of Contents
USE OF PROCEEDS
We estimate that the net proceeds from the sale of the shares of common stock that we are offering will be approximately
$ million, or approximately $ million if the underwriters exercise in full their option to
purchase up to additional shares of common stock,
based on the public offering price of $ per share and after deducting the underwriting discount and estimated offering expenses payable by us.
We
currently intend to use the net proceeds from the sale of the shares of common stock offered by us hereunder for general corporate purposes, including working capital, continued
development of our product candidate pipeline, acquisitions and other business opportunities.
The
amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing and progress of our pre-clinical studies and clinical
trials, research and development efforts, the timing and progress of any partnering and commercialization efforts and technological advances. As of the date of this prospectus supplement, we cannot
specify with certainty all of the particular uses for the net proceeds to us from the sale of the shares of common stock offered by us hereunder. Accordingly, our management will have broad discretion
in the timing and application of these proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in short-term, interest-bearing instruments,
such as mutual and money market funds, bank certificates of deposit and investment-grade commercial paper, corporate notes, and government securities.
S-12
Table of Contents
DILUTION
If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the
offering price per share and our as adjusted net tangible book value per share immediately after this offering. We calculate net tangible book value per share by dividing our net tangible book value,
which is tangible assets less total liabilities (excluding contingent consideration and deferred taxes related to the intangible assets), by the number of outstanding shares of our common stock.
Our
net tangible book value as of December 31, 2014 was approximately $23.3 million, or $1.04 per share. After giving effect to the assumed sale by us
of
shares of common stock in this offering at the public offering price of $ per share and after deducting the underwriting discount and estimated offering expenses payable by us,
our as
adjusted net tangible book value, as of December 31, 2014, would have been approximately $ million, or
$ per share of common stock. This represents an
immediate increase in the net tangible book value of $ per share to our existing stockholders and an immediate dilution in the net tangible book value of
$ per share of
common stock to investors purchasing common stock in this offering. The following table illustrates this calculation on a per share basis:
|
|
|
|
|
|
|
|
Assumed offering price per share of common stock |
|
|
|
|
$ |
|
|
Net tangible book value per share as of December 31, 2014 |
|
$ |
1.04 |
|
|
|
|
Increase in net tangible book value per share after this offering |
|
$ |
|
|
|
|
|
As adjusted net tangible book value per share as of December 31, 2014, after giving effect to this offering |
|
|
|
|
$ |
|
|
Dilution per share to investors participating in this offering |
|
|
|
|
$ |
|
|
If
the underwriters exercise in full their option to purchase up
to additional shares of common
stock in this offering at the public offering price of $
per share, the as adjusted net tangible book value per share after this offering would be $ per share, representing an increase in the net tangible book value of
$ per
share to existing stockholders and immediate dilution in net tangible book value of $ per share to new investors purchasing our common stock in this offering.
The
number of shares of our common stock to be outstanding immediately after this offering is based on 22,334,901 shares of common stock outstanding as of December 31, 2014.
Unless specifically stated otherwise, the information in this prospectus supplement is as of December 31, 2014 and excludes:
-
- 3,277,308 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2014, at a
weighted average exercise price of $5.53 per share, of which options to purchase 1,690,999 shares of our common stock were then exercisable;
-
- 21,786 shares of our common stock issuable upon the exercise of warrants issued in 2006, and which remained outstanding as of
December 31, 2014, each with an exercise price of $7.65 per share, 10,893 of which will be exercisable until March 30, 2016 and 10,893 of which will be exercisable until May 5,
2016;
-
- 1,961 shares of our common stock issuable upon the exercise of warrants issued in 2007, and which remained outstanding as of
December 31, 2014, each with an exercise price of $7.65 per share, all of which will be exercisable until May 2, 2017;
-
- 52,815 shares of our common stock issuable upon the exercise of warrants issued in 2009 and 2010, and which remained outstanding as of
December 31, 2014, each with an exercise price of
S-13
Table of Contents
$0.85
per share, 24,007 of which will be exercisable until November 25, 2019 and 28,808 of which will be exercisable until March 10, 2020;
-
- an aggregate of 2,942,629 shares of our common stock reserved for future grants under our 2004 Equity Incentive Plan, as amended, and
our Amended and Restated 2013 Equity Incentive Plan as of December 31, 2014;
-
- 524,304 shares of our common stock issued in exchange for an aggregate principal amount of notes of $3,250,000 under exchange
agreements dated March 3, 2015;
-
- 7,137,031 shares of our common stock that are issuable upon conversion of our aggregate principal amount of notes of $43,750,000 plus
interest-make-whole payments, as of the date hereof; and
-
- 450,000 shares of restricted common stock granted to executive officers, and options to purchase 705,000 shares of our common stock at
$5.25 per share granted to executive officers, directors, and employees, effective January 28, 2015.
S-14
Table of Contents
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of
the purchase, ownership and disposition of our common stock issued pursuant to this offering. This summary is not a complete analysis of all potential tax effects and does not discuss the application
of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws. This discussion is based on the Code, Treasury Regulations promulgated
thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case as in effect on the date hereof. These
authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder of
our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to
that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock.
This
discussion is limited to Non-U.S. Holders that hold our common stock as a "capital asset" within the meaning of Section 1221 of the Code (generally, property held for
investment). This discussion does
not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder's particular circumstances, including the impact of the Medicare contribution tax on net investment income. In
addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation:
-
- U.S. expatriates and former citizens or long-term residents of the United States;
-
- persons subject to the alternative minimum tax;
-
- persons holding our common stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction
or other integrated investment;
-
- banks, insurance companies and other financial institutions;
-
- brokers, dealers or traders in securities;
-
- "controlled foreign corporations," "passive foreign investment companies" and corporations that accumulate earnings to avoid U.S.
federal income tax;
-
- partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
-
- tax-exempt organizations or governmental organizations;
-
- persons deemed to sell our common stock under the constructive sale provisions of the Code;
-
- persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and
-
- tax-qualified retirement plans.
If
an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the
partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult
their tax advisors regarding the U.S. federal income tax consequences to them.
THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.
FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR
S-15
Table of Contents
SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL
OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.
Definition of a Non-U.S. Holder
For purposes of this discussion, a "Non-U.S. Holder" is any beneficial owner of our common stock that is neither a "U.S. person" nor an
entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the
following:
-
- an individual who is a citizen or resident of the United States;
-
- a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;
-
- an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
-
- a trust that (1) is subject to the primary supervision of a U.S. court and all substantial decisions of which are under the
control of one or more "United States persons" (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for
U.S. federal income tax purposes.
Distributions
We do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make
distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against
and reduce a Non-U.S. Holder's adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under "Sale or
Other Taxable Disposition."
Subject
to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30%
of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other
applicable documentation) certifying qualification for the lower treaty rate. A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate,
may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to
benefits under any applicable income tax treaty.
If
dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States (and, if required by an applicable
income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal
withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are
effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States.
Any
such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may
be
S-16
Table of Contents
subject
to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits that are attributable to such
dividends, as
adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules.
Sale or Other Taxable Disposition
A Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our
common stock unless:
-
- the gain is effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United States (and, if required
by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable);
-
- the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year
of the disposition and certain other requirements are met; or
-
- our common stock constitutes a U.S. real property interest ("USRPI") by reason of our status as a U.S. real property holding
corporation ("USRPHC") for U.S. federal income tax purposes.
Gain
described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a
corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits that are
attributable to such gain, as adjusted for certain items.
Gain
described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may
be offset by
U.S.-source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax
returns with respect to such losses.
With
respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends on
the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or
will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a Non-U.S. Holder of our common stock will not be subject to
U.S. federal income tax if our common stock is "regularly traded," as defined by applicable Treasury Regulations, on an established securities market, and such Non-U.S. Holder owned, actually and
constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder's holding period.
Non-U.S.
Holders should consult their tax advisors regarding applicable income tax treaties that may provide for different rules.
Information Reporting and Backup Withholding
Payments of dividends on our common stock to Non-U.S. Holders will not be subject to backup withholding, provided the holder either
certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed
with the IRS with respect to any dividends on our common stock paid to the Non-U.S. Holder, regardless of whether any tax was actually withheld. Proceeds of the sale or other taxable disposition of
our common stock within the United States or conducted through certain
S-17
Table of Contents
U.S.-related
brokers generally will not be subject to backup withholding or information reporting, provided the applicable withholding agent receives the certification described above, or the holder
otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a non-U.S. office of a non-U.S. broker that does not have certain enumerated relationships with the
U.S. generally will not be subject to backup withholding or information reporting.
Copies
of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or tax information exchange agreement to the tax
authorities of the country in which the Non-U.S. Holder resides or is established.
Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder's U.S. federal
income tax liability, provided the required information is timely furnished to the IRS.
Additional Withholding Tax on Payments Made to Foreign Accounts
Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (commonly referred to as the Foreign Account Tax
Compliance Act or "FATCA") on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Under FATCA, a 30% withholding tax may be imposed on dividends on,
or gross proceeds from the sale or other disposition of, our common stock paid to a "foreign financial institution" or a "non-financial foreign entity" (each as defined in the Code), unless
(1) the foreign financial institution undertakes certain diligence and reporting obligations, (2) the non-financial foreign entity either certifies it does not have any "substantial
United States owners" (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial
foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements described in
(1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain "specified United
States persons" or "United States-owned foreign entities" (each as defined in the Code), annually report certain information about such accounts and withhold 30% on certain payments to non-compliant
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing
FATCA may be subject to different rules.
Under
the applicable Treasury Regulations, withholding under FATCA generally applies to payments of dividends on our common stock, and will apply to payments of gross proceeds from the
sale or other disposition of such stock on or after January 1, 2017.
Prospective
investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock.
S-18
Table of Contents
UNDERWRITING
Under the terms and subject to the conditions to be set forth in an underwriting agreement, dated as of May ,
2015, by and between us and William Blair & Company, L.L.C. and Nomura Securities International, Inc., acting as representatives for the underwriters named below, we have agreed to sell
to the underwriters, and the underwriters have agreed to purchase from us, the following respective number of shares common stock:
|
|
|
|
|
Underwriter
|
|
Number of Shares |
|
William Blair & Company, L.L.C. |
|
|
|
|
Nomura Securities International, Inc. |
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers' certificates
and legal opinions. The underwriting agreement provides that the underwriters will purchase all of the shares if any of them are purchased. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those
liabilities.
The
underwriters are offering the shares subject to their acceptance of the shares from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify
offers to the public and to reject orders in whole or in part.
Option to Purchase Additional Shares
We have granted the underwriters an option, exercisable no later than 30 calendar days after the date of the underwriting agreement, to
purchase up to an aggregate of additional shares at the public offering price, less the underwriting discount set forth on the
cover page of this prospectus supplement and as indicated
below. We will be obligated to sell these shares to the underwriters to the extent the option is exercised.
Discount and Expenses
The underwriters have advised us that they propose to offer the shares of common stock directly to the public at the offering price set
forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of $ per share. After this offering, the public offering
price
and the concession to dealers may be reduced by the underwriters. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus
supplement.
The
following table shows the per share and total underwriting discount that we will pay to the underwriters and the proceeds we will receive before expenses. These amounts are shown
assuming both no exercise and full exercise of the underwriters' option to purchase additional shares.
|
|
|
|
|
|
|
|
|
|
|
|
|
PER
SHARE |
|
TOTAL
WITHOUT
OVER-ALLOTMENT
EXERCISE |
|
TOTAL
WITH
OVER-ALLOTMENT
EXERCISE |
|
Public offering price |
|
$ |
|
|
$ |
|
|
$ |
|
|
Underwriting discount |
|
$ |
|
|
$ |
|
|
$ |
|
|
Proceeds to TetraLogic Pharmaceuticals Corporation before expenses |
|
$ |
|
|
$ |
|
|
$ |
|
|
S-19
Table of Contents
We
have also agreed to reimburse the underwriters for certain of their expenses in an amount not to exceed $25,000. We estimate the total offering expenses of this offering that will be
payable by us, excluding the underwriting discount, will be approximately $ , which includes legal costs and various other fees.
No Sales of Similar Securities
We have agreed with the underwriters, subject to specified exceptions not to (i) offer, sell, contract to sell, pledge, grant
any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with the SEC a registration statement under the Act
relating to, any securities of the Company that are substantially similar to the Securities, including but not limited to any options or warrants to purchase shares of Stock or any securities that are
convertible into or exchangeable for, or that represent the right to receive, Stock, or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge,
disposition or filing or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock, or any such other
securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior
written consent of William Blair & Company, L.L.C.
Our
directors and executive officers have agreed, subject to certain exceptions, with the underwriters not to directly or indirectly (i) offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any common stock or any
securities convertible into or exchangeable or exercisable for common stock, whether now owned or hereafter acquired by such director or executive officer or with respect to which such director or
executive officer has or hereafter acquires the power of disposition, or file, make any demand with respect to, cause to be filed, or exercise any right with respect to any registration statement
under the Securities Act with respect to any of the foregoing or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly,
the economic consequence of ownership of the common stock, whether any such swap or transaction is to be settled by delivery of common stock or other securities, in cash or otherwise. The lock-up
agreements do not prohibit our directors or executive officers from transferring shares of our common stock for bona fide gifts or other estate and tax planning purposes, subject to certain
requirements, including that the transferee be subject to the same lock-up terms. The lock-up agreements do not prohibit us from issuing shares of common stock to our directors or executive officers
upon exercise of options or warrants or vesting of restricted stock outstanding on the date of this prospectus supplement.
These
restrictions will apply through and including the date that is 90 days after the date of this prospectus supplement.
William
Blair & Company, L.L.C. may at their discretion and at any time or from time to time before the termination of the 90-day restricted period, without public notice, release
all or any portion of the securities subject to lock up agreements. There are no existing agreements between the underwriters and us, providing consent to the sale of shares prior to the expiration of
the lock up period.
NASDAQ Global Market Listing
Our common stock is listed on the NASDAQ Global Market under the symbol "TLOG".
Price Stabilization and Short Positions
Until the distribution of the common stock is completed, SEC rules may limit the underwriters from bidding for and purchasing our
common stock.
S-20
Table of Contents
In
connection with this offering, the underwriters may engage in transactions that stabilize, maintain or otherwise make short sales of our common stock and may purchase shares of our
common stock in the open market to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in this
offering. The underwriters may close out any short position by purchasing shares of our common stock in the open market or exercising their option to purchase additional shares. A short position is
more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors
who purchase in this offering. The underwriters may also engage in "stabilizing bids," which are bids for or the purchase of shares of our common stock on behalf of the underwriters in the open market
prior to the completion of this offering for the purpose of fixing or maintaining the price of our common stock.
The
underwriters' purchases to cover short sales, as well as other purchases by the underwriters for their own account, and stabilizing bids may have the effect of raising or maintaining
the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might
otherwise exist in the open market.
In
connection with this offering, the underwriters may also engage in passive market making transactions in our common stock on the NASDAQ Global Market in accordance with
Rule 103 of Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A
passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker's bid,
that bid must then be lowered when specified purchase limits are exceeded.
Neither
we, nor the underwriters, make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our
common
stock. In addition, neither we nor the underwriters makes any representation that the underwriters will engage in these transactions or that any transaction, if commenced, will not be discontinued
without notice.
Affiliations
The underwriters and their affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The
underwriters and their affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will
receive customary fees and expenses.
In
the ordinary course of their various business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities
activities may involve securities and/or instruments of ours. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in
respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short position in such securities and instruments.
Selling Restrictions
Sales of the common stock made outside of the United States may be made by affiliates of certain of the underwriters.
S-21
Table of Contents
Canada
The shares of common stock may be sold only to purchasers purchasing as principal that are both "accredited investors" as defined in
National Instrument 45-106 Prospectus and Registration Exemptions and "permitted clients" as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing
Registrant Obligations. Any resale of the shares of common stock must be made in accordance with an exemption from the prospectus requirements and in compliance with the registration requirements of
applicable securities laws.
European Economic Area
In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, each, a Relevant Member
State, an offer to the public of any shares of our common stock may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any shares of our
common stock may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:
- (a)
- to
any legal entity which is a qualified investor as defined in the Prospectus Directive;
- (b)
- to
fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons
(other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer;
or
- (c)
- in
any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares of our common stock shall
result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive.
For
the purposes of this provision, the expression an "offer to the public" in relation to any shares of our common stock in any Relevant Member State means the communication in any form
and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase any shares of our common stock,
as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression "Prospectus Directive" means Directive 2003/71/EC (and
amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and
the expression "2010 PD Amending Directive" means Directive 2010/73/EU.
United Kingdom
Each underwriter has represented and agreed that:
- (a)
- it
has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in
investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000, or the FSMA) received by it in connection with the issue or sale of the shares of our
common stock in circumstances in which Section 21(1) of the FSMA does not apply to us; and
- (b)
- it
has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock
in, from or otherwise involving the United Kingdom.
S-22
Table of Contents
Hong Kong
The common shares may not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not
constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii) to "professional investors" within the meaning of the Securities and
Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a "prospectus" within the meaning of the
Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue
(in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the
laws of Hong Kong) other than with respect to common shares which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the
Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder.
Singapore
This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any
other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the common shares may not be circulated or distributed, nor may the common shares be
offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under
Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to
Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA.
Where
the common shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is:
- a)
- a
corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the
entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- b)
- a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is
an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred
within six months after that corporation or that trust has acquired the common shares pursuant to an offer made under Section 275 of the SFA except:
- i)
- to
an institutional investor (for corporations, under Section 274 of the SFA) or to a relevant person defined in Section 275(2) of the SFA, or
to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a
consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and
further for corporations, in accordance with the conditions specified in Section 275 of the SFA;
- ii)
- where
no consideration is or will be given for the transfer; or
- iii)
- where
the transfer is by operation of law.
S-23
Table of Contents
Switzerland
The common shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of
the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading
facility in Switzerland. Neither this document nor any other offering or marketing material relating to the common shares or this offering may be publicly distributed or otherwise made publicly
available in Switzerland.
Neither
this document nor any other offering or marketing material relating to this offering, or the common shares have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of common shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of
common shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. Accordingly, no public distribution, offering or advertising, as defined in
CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA, its implementing ordinances and notices, shall be undertaken in or from
Switzerland, and the investor protection afforded to acquirers of interests in collective investment schemes under CISA does not extend to acquirers of common shares.
Japan
The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No. 25 of
1948, as amended), or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or
any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except
pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan.
S-24
Table of Contents
LEGAL MATTERS
The validity of the shares of common stock offering by this prospectus is being passed upon for us by Pepper Hamilton LLP,
Philadelphia, Pennsylvania. In connection with this offering, Latham & Watkins LLP, Chicago, Illinois, advised the underwriters with respect to certain U.S. securities law matters.
EXPERTS
The consolidated financial statements of TetraLogic Pharmaceuticals Corporation appearing in TetraLogic Pharmaceutical Corporation's
Annual Report (Form 10-K) for the year ended December 31, 2014 have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their
report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority
of such firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
This prospectus supplement and the accompanying prospectus are part of the registration statement on Form S-3 we filed with the
SEC under the Securities Act and do not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement and the accompanying prospectus
to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the
reports or other documents incorporated herein by reference for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the
Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at
http://www.sec.gov. You may also read and copy any document we file at the SEC's Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the operation of the Public Reference Room.
We
make available free of charge on our website our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically
file such material with, or furnish such material to, the SEC. Please note, however, that we have not incorporated any other information by reference from our website, other than the documents listed
under the heading "Incorporation of Certain Information by Reference." In addition, you may request copies of these filings at no cost, by writing or telephoning us at the following address or
telephone number:
TetraLogic
Pharmaceuticals Corporation
343 Phoenixville Pike
Malvern, PA 19355
Attn: Richard L. Sherman, Esq.
(610) 889-9900
S-25
Table of Contents
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to "incorporate by reference" information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement. Information in this prospectus
supplement supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement, while information that we file later with the SEC will
automatically update and supersede the information in this prospectus supplement. We incorporate by reference into this prospectus supplement, the accompanying prospectus and the registration
statement of which this prospectus supplement and the accompanying prospectus are a part the information or documents listed below that we have filed with the SEC (File
No. 001-36208):
-
- Our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 that we filed with the SEC on
February 26, 2015 (including the portions of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 9, 2015 incorporated by reference therein);
-
- Our Current Reports on Form 8-K filed with the SEC on March 3, 2015, March 13, 2015 (File No. 15698098),
March 13, 2015 (File No. 15700312), March 23, 2015, April 20, 2015 and April 30, 2015; and
-
- The description of our common stock contained in our registration statement on Form S-1 (333-191811), which description is
incorporated by reference into the Form 8-A filed with the SEC on November 18, 2013 (Registration No. 001-36208) pursuant to the Exchange Act, and any amendment or report filed
for the purpose of further updating such description.
We
also incorporate by reference any future filings (other than any filings or portions of such reports that are not deemed "filed" under the Exchange Act in accordance with the Exchange
Act and applicable SEC rules, including current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items unless
such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial
filing of the registration statement of which this prospectus supplement is a part, until we file a post-effective amendment that indicates the termination
of this offering of the securities made by this prospectus supplement and will become a part of this prospectus supplement from the date that such documents are filed with the SEC. Information in such
future filings updates and supplements the information provided in this prospectus supplement. Any statements in any such future filings will automatically be deemed to modify and supersede any
information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or
replace such earlier statements.
To
obtain copies of these filings, see "Where You Can Find More Information" on page S-29.
S-26
PROSPECTUS
TetraLogic Pharmaceuticals Corporation
$150,000,000
Common Stock, Preferred Stock,
Debt Securities, Warrants, Units And Subscription Rights
This prospectus covers our offer and sale from time to time of any combination of common stock, preferred stock, debt securities, warrants, units
or subscription rights described in this prospectus in one or more offerings. This prospectus provides a general description of the securities we may offer and sell. Each time we offer and sell
securities we will provide specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this
prospectus. The aggregate offering price of all securities sold by us under this prospectus may not exceed $150,000,000.
The
securities may be offered and sold by us from time to time at fixed prices, at market prices or at negotiated prices, and may be offered and sold to or through one or more
underwriters, dealers or agents or directly to purchasers on a continuous or delayed basis. See "Plan of Distribution" in this prospectus and in the applicable prospectus supplement.
Our
common stock is currently listed on NASDAQ under the symbol "TLOG". On December 31, 2014, the last reported sale price of our common stock on NASDAQ was $4.82 per share.
You
should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized any other person to provide you with different information.
Investing in these securities involves risks, including those set forth in the "Risk Factors" section of our most recent Annual Report on
Form 10-K, as revised or
supplemented by our Quarterly Reports on Form 10-Q filed with the SEC since the filing of our most recent Annual Report on Form 10-K, each of which is incorporated by reference into this
prospectus. We may include specific risk factors in supplements to this prospectus under the caption "Risk Factors." This prospectus may not be used to sell our securities unless accompanied by a
prospectus supplement.
Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful and complete. Any
representation to the contrary is a criminal offense.
This prospectus is dated January 15, 2015.
We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by
reference in this prospectus and any accompanying supplement to this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus
or any accompanying prospectus supplement. This prospectus and any accompanying supplement to this prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities
other than the registered securities to which they relate, nor do this prospectus and any accompanying supplement to this prospectus constitute an offer to sell or the solicitation of an offer to buy
securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. "TetraLogic," "Company," "we," "us" and "our" refer to TetraLogic
Pharmaceuticals Corporation and its consolidated subsidiaries.
TABLE OF CONTENTS
|
|
|
|
|
|
|
Page |
|
ABOUT THIS PROSPECTUS |
|
|
1 |
|
WHERE YOU CAN FIND MORE INFORMATION |
|
|
1 |
|
INCORPORATION OF INFORMATION BY REFERENCE |
|
|
1 |
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |
|
|
2 |
|
RISK FACTORS |
|
|
3 |
|
TETRALOGIC PHARMACEUTICALS CORPORATION |
|
|
3 |
|
USE OF PROCEEDS |
|
|
4 |
|
RATIO OF EARNINGS TO FIXED CHARGES |
|
|
4 |
|
DESCRIPTION OF SECURITIES |
|
|
4 |
|
DESCRIPTION OF CAPITAL STOCK |
|
|
5 |
|
DESCRIPTION OF DEBT SECURITIES |
|
|
6 |
|
DESCRIPTION OF WARRANTS |
|
|
9 |
|
DESCRIPTION OF UNITS |
|
|
9 |
|
DESCRIPTION OF SUBSCRIPTION RIGHTS |
|
|
9 |
|
PLAN OF DISTRIBUTION |
|
|
9 |
|
EXPERTS |
|
|
11 |
|
LEGAL MATTERS |
|
|
11 |
|
i
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the "SEC"). This
prospectus covers the primary offering by us of up to an aggregate of $150,000,000 of securities. We may offer and sell any combination of the securities described in this prospectus in one or more
offerings. This prospectus provides you with a general description of the securities we may offer and sell. Each time we offer and sell securities under this prospectus, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read
both this prospectus and any prospectus supplement together with additional information described under the heading "Where You Can Find More Information."
We
have filed or incorporated by reference exhibits to the registration statement of which this prospectus forms a part. You should read the exhibits carefully for provisions that
may be important to you.
This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document
we file with the SEC at the SEC's public reference room at 100 F Street NE, Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the SEC's public reference
facilities by calling the SEC at 1-800-SEC-0330. You can request copies of these documents, upon payment of a duplicating fee, by writing to the SEC at its principal office at 100 F Street NE,
Room 1580, Washington, D.C. 20549-1004. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding
issuers that file electronically with the SEC. Our SEC filings are accessible through the Internet at that website. Our reports on Forms 10-K, 10-Q and 8-K, and amendments to those reports, are
also available for download, free of charge, as soon as reasonably practicable after these reports are filed with the SEC, at our website at www.tlog.com. The content contained in, or that can be
accessed through, our website is not a part of this prospectus.
INCORPORATION OF INFORMATION BY REFERENCE
The SEC allows us to "incorporate by reference" the information we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with the SEC will automatically
update and supersede this information. We incorporate by reference the documents listed below:
-
- Our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 that we filed with the SEC on
March 19, 2014;
-
- Our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014 that we filed with the SEC on
May 8, 2014, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2014 that we filed with the SEC on August 5, 2014 and our Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2014 that we filed with the SEC on November 5, 2014;
-
- Our Current Reports on Form 8-K filed with the SEC on January 8, 2014, January 31, 2014, April 11, 2014,
April 14, 2014, May 19, 2014, June 5, 2014, June 18, 2014 (Film Number 14926623), June 23, 2014, and November 10, 2014;
1
-
- The description of the Registrant's Common Stock contained in the Registrant's registration statement on the Form S-1, which
description is incorporated by reference into the Form 8-A filed with the SEC on November 18, 2013 (Registration No. 001-36208) pursuant to the Securities Exchange Act of 1934, as
amended, or the Exchange Act, and any amendment or report filed for the purpose of further updating such description;
-
- All documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the
initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement; and
-
- All documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date
of this prospectus and before we stop offering the securities under this prospectus.
We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written or oral request, a copy of any or all
documents referred to above which have been or may be incorporated by reference into this prospectus but not delivered with this prospectus excluding exhibits to those documents unless they are
specifically incorporated by reference into those documents. You can request those documents from Pete A. Meyers, Chief Financial Officer and Treasurer at 343 Phoenixville Pike, Malvern, Pennsylvania
19355, telephone (610) 889-9900.
The
most recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of
this prospectus, commencing on the date on which the filing is made.
Information
furnished under Items 2.02 or 7.01 (or corresponding information furnished under Item 9.01 or included as an exhibit) in any past or future Current Report on
Form 8-K that we file with the SEC, unless otherwise specified in such report, is not incorporated by reference in this prospectus.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference in this prospectus contain forward-looking statements. All statements that
address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. In some cases, you can identify forward-looking statements
by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify
forward-looking statements.
These
forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these
forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when
made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In
addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our
present expectations or projections. Before making an investment decision, you should carefully consider these risks as well as any other information we include or incorporate by reference in this
prospectus or include in any applicable prospectus supplement. You should read this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus
forms a part in their entireties.
2
RISK FACTORS
Our business is influenced by many factors that are difficult to predict, and that involve uncertainties that may materially affect
actual operating results, cash flows and financial condition. Before making an investment decision, you should carefully consider these risks, including those set forth in the "Risk Factors" section
of our most recent Annual Report on Form 10-K, as revised or supplemented by our Quarterly Reports on Form 10-Q filed with the SEC since the filing of our most recent Annual Report on
Form 10-K, each of which is incorporated by reference into this prospectus, and you should also carefully consider any other information we include or incorporate by reference in this
prospectus or include in any applicable prospectus supplement.
TETRALOGIC PHARMACEUTICALS CORPORATION
Overview
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology
and infectious diseases. We currently have two clinical-stage product candidates in development: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester, or SHAPE.
Birinapant is a novel small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases, or SMAC-mimetic, which leads to
apoptosis, or cell-death, in damaged cells. We have treated over 300 oncology subjects with birinapant, and in non-randomized studies to date, we have seen activity in subjects with (i) higher
risk myelodysplastic syndromes, or MDS, where we have observed complete responses in combination with azacitidine (Vidaza®); (ii) end-stage acute myeloid leukemia, where as a
single-agent, birinapant caused declines in blast counts previously relapsed or refractory to standard therapy; (iii) ovarian cancer, where in combination with conatumumab, we have observed
disease stabilization and a partial response in women who previously relapsed or were refractory to standard therapy; and (iv) colorectal cancer where, in combination with irinotecan, we have
observed evidence of anti-tumor activity or prolonged disease stabilization in subjects who have progressed after multiple prior therapies, including irinotecan.
Most
recently, we have generated pre-clinical data indicating that birinapant induces apoptosis in-vivo in mouse hepatocytes infected with human hepatitis B virus, or HBV. In a mouse
model, we have seen clearance of HBV surface antigen, or HBsAg, and the appearance of antibodies directed against HBsAg, a clinical finding considered equivalent to a functional cure. We have also
seen activity of birinapant in other infectious disease models, including human mononuclear cells infected with human immunodeficiency virus, or HIV, in-vitro, and in-vivo in mouse models of
Mycobacterium tuberculosis and Legionella pneumophila.
We
are currently conducting the following three clinical programs with birinapant:
-
- In June 2014, we commenced a randomized, double-blind placebo-controlled phase 2 clinical trial of birinapant in combination
with azacitidine in subjects with previously untreated, higher risk MDS. Interim data is expected in 2015. This clinical trial follows our phase 1b/2a open-label clinical trial of birinapant in
combination with azacitidine.
-
- We are continuing enrollment in a phase 1/2 clinical trial of birinapant in combination with conatumumab in third-line ovarian cancer.
In December 2014, this clinical trial proceeded into a phase 2a expansion based upon data in the phase 1 portion of the clinical trial. Phase 2a clinical trial data is expected in
2015.
-
- We recently initiated a randomized, placebo-controlled, multiple ascending dose phase 1 clinical trial in subjects with chronic
HBV currently taking entecavir or tenofovir. Data is expected in 2015.
3
We
discovered birinapant, and its composition of matter patent in the U.S. extends until at least 2030. TetraLogic has retained worldwide development and commercialization rights for all
indications.
SHAPE,
our second clinical-stage product candidate, is a histone deacetylase, or HDAC, inhibitor that we are developing for topical use for the treatment of cutaneous T-cell lymphoma, or
CTCL. HDAC is a validated cancer target, and HDAC inhibitors are a proven class of anti-cancer drugs for CTCL. SHAPE is a novel therapeutic, designed to maximize HDAC inhibition locally in the skin
with limited systemic exposure, and it has characteristics that could allow its topical use over large body surface areas with minimal systemic absorption. By potentially avoiding toxicities typical
of systemically-administered HDAC inhibitors, SHAPE may provide a more favorable safety profile than current HDAC inhibitors delivered orally or intravenously. SHAPE has been evaluated in a
randomized, placebo-controlled dose escalation phase 1 clinical trial in early-stage CTCL. SHAPE was well-tolerated, and it demonstrated evidence of clinical activity with partial responses
observed in certain subjects after 28 days of application. We have commenced a randomized phase 2 clinical trial of SHAPE in subjects with early-stage CTCL, which will assess clinical
activity after six months of application. Data for this clinical trial is expected in 2015.
SHAPE's
composition of matter patent in the U.S. extends until at least 2028. In addition, SHAPE has been granted U.S. orphan drug designation for CTCL. We have acquired worldwide
development and commercialization rights to SHAPE for all indications.
You
can get more information regarding our business and industry by reading our most recent Annual Report on Form 10-K and the other reports we file with the SEC. See "Where You
Can Find More Information" and "Incorporation of Information by Reference."
Corporate Information
Our principal executive offices are located at 343 Phoenixville Pike, Malvern, Pennsylvania 19355, and our telephone number is
(610) 889-9900. Our website address is www.tlog.com. The content contained in, or that can be accessed through, our website is not part of this prospectus.
USE OF PROCEEDS
Unless otherwise indicated in a prospectus supplement, we anticipate that the net proceeds from our sale of any securities will be used
for general corporate purposes, including working capital, continued development of our product candidate pipeline, acquisitions, retirement of debt and other business opportunities.
RATIO OF EARNINGS TO FIXED CHARGES
Any time debt securities are offered pursuant to this prospectus, we will provide a table setting forth our ratio of earnings to fixed
charges on a historical basis in the applicable prospectus supplement, if required.
DESCRIPTION OF SECURITIES
We may offer shares of our common stock and preferred stock, various series of debt securities, warrants or units or subscription
rights to purchase any of such securities, with a total value of up to $150,000,000, from time to time in one or more offerings under this prospectus at prices and on terms to be determined by market
conditions at the time of the offering. This prospectus provides you with a general description of the securities that we may offer. In connection with each offering, we will provide a prospectus
supplement that will describe the specific amounts, prices and terms of the securities being offered, including, to the extent applicable:
-
- designation or classification;
4
-
- aggregate offering price;
-
- rates and times of payment of dividends;
-
- redemption, conversion or exchange terms;
-
- conversion or exchange prices or rates and any provisions for changes to or adjustments in the conversion or exchange prices or rates
and in the securities or other property receivable upon conversion or exchange;
-
- restrictive covenants;
-
- voting or other rights; and
-
- important federal income tax considerations.
The
prospectus supplement also may add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement
will offer a security that is not included in the Registration Statement at the time of its effectiveness or offer a security of a type that is not described in this prospectus.
DESCRIPTION OF CAPITAL STOCK
Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.0001 per share, and 25,000,000 shares of
preferred stock, par value $0.0001 per share. As of September 30, 2014, 22,307,138 shares of our common stock, and no shares of our preferred stock, were outstanding.
Common Stock
Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, other
than election of directors, which shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election of such director. In addition, the affirmative vote of the
holders of at least 75% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our amended and restated
certificate of incorporation, such as the provisions relating to the classified board and director liability, the prohibition on action by written consent of the stockholders in lieu of a meeting of
stockholders, amending our bylaws, removing directors without cause or changing the Court of Chancery of the State of Delaware from being the sole and exclusive forum for certain actions brought by
our stockholders against us or our directors, officers or employees.
Subject to the preferences that may be applicable to any outstanding preferred stock, holders of our common stock shall be entitled to
receive ratably any dividends that may be declared by the board of directors out of funds legally available for that purpose.
In the event of our liquidation, dissolution or winding up, holders of our common stock shall be entitled to share ratably in all
assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock.
Our common stock shall not be entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions.
5
Preferred Stock
We may issue any class of preferred stock in any series. Our board of directors has the authority to establish and designate series,
and to fix the number of shares included in each such series and the variations in the relative rights, preferences and limitations as between series, provided that, if the stated dividends and
amounts payable on liquidation are not paid in full, the shares of all series of the same class shall share ratably in the payment of dividends including accumulations, if any, in accordance with the
sums which would be payable on such shares if all dividends were declared and paid in full, and in any distribution of assets other than by way of dividends in accordance with the sums which would be
payable on such distribution if all sums payable were discharged in full. Shares of each series when issued shall be designated to distinguish the shares of each series from shares of all other
series. Our board of directors also can increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding.
Our
board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the
common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of
delaying, deferring or preventing a change in control of our company and may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock.
DESCRIPTION OF DEBT SECURITIES
This prospectus describes certain general terms and provisions of our debt securities. When we offer to sell a particular series of
debt securities, we will describe the specific terms of the series in a supplement to this prospectus. The following description of debt securities will apply to the debt securities offered by this
prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of debt securities may specify different or additional
terms.
We
may offer under this prospectus up to $150,000,000 aggregate principal amount of secured or unsecured debt securities, or if debt securities are issued at a discount, or in a foreign
currency or composite currency, such principal amount as may be sold for a public offering price of up to $150,000,000. The debt securities may be either senior debt securities, senior subordinated
debt securities or subordinated debt securities. The debt securities offered hereby will be issued under an indenture between us and a trustee. A form of indenture, which will be qualified under,
subject to, and governed by, the Trust Indenture Act of 1939, as amended, is filed as an exhibit to the registration statement.
General
The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and detailed
or determined in the manner provided in a board of directors' resolution, an officers' certificate or by an indenture. The particular terms of each series of debt securities will be described in a
prospectus supplement relating to the series, including any pricing supplement.
We
can issue debt securities that may be in one or more series with the same or various maturities, at par, at a premium or at a discount. We will set forth in a prospectus supplement,
including any pricing supplement, relating to any series of debt securities being offered, the initial offering price, the aggregate principal amount and the following terms of the debt
securities:
-
- the title of the debt securities;
6
-
- the price or prices (expressed as a percentage of the aggregate principal amount) at which we will sell the debt securities;
-
- any limit on the aggregate principal amount of the debt securities;
-
- the date or dates on which we will pay the principal on the debt securities;
-
- the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any
commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which
interest will commence and be payable and any regular record date for the interest payable on any interest payment date;
-
- the place or places where the principal of, and premium and interest on, the debt securities will be payable;
-
- the terms and conditions upon which we may redeem the debt securities;
-
- any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at the option
of a holder of debt securities;
-
- the dates on which and the price or prices at which we will repurchase the debt securities at the option of the holders of debt
securities and other detailed terms and provisions of these repurchase obligations;
-
- the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple
thereof;
-
- whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
-
- the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than
the principal amount;
-
- the currency of denomination of the debt securities;
-
- the designation of the currency, currencies or currency units in which payment of principal of, and premium and interest on, the debt
securities will be made;
-
- if payments of principal of, and premium or interest on, the debt securities will be made in one or more currencies or currency units
other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined;
-
- the manner in which the amounts of payment of principal of, and premium or interest on, the debt securities will be determined, if
these amounts may be determined by reference to an index based on a currency or currencies other than that in which the debt securities are denominated or designated to be payable or by reference to a
commodity, commodity index, stock exchange index or financial index;
-
- any provisions relating to any security provided for the debt securities;
-
- any addition to or change in the events of default described in this prospectus or in the indenture with respect to the debt
securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities;
-
- any addition to or change in the covenants described in this prospectus or in the indenture with respect to the debt securities;
7
-
- any other terms of the debt securities, which may modify or delete any provision of the indenture as it applies to that series; and
-
- any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt
securities.
We
may issue debt securities that are exchangeable and/or convertible into other securities. The terms, if any, on which the debt securities may be exchanged and/or converted will be set
forth in the applicable prospectus supplement. Such terms may include provisions for conversion, either mandatory, at the option of the holder or at our option, in which case the number of securities
to be received by the holders of debt securities would be calculated as of a time and in the manner stated in the prospectus supplement.
We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the
terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable
prospectus supplement.
If
we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit or units, or if the principal of and any premium and
interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the restrictions, elections,
general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the
applicable prospectus supplement.
Payment of Interest and Exchange
Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company,
as Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security as a book-entry debt security), or a certificate issued in definitive registered
form (we will refer to any debt security represented by a certificated security as a certificated debt security), as described in the applicable prospectus supplement.
Certificated Debt Securities
You may transfer or exchange certificated debt securities at the trustee's office or paying agencies in accordance with the terms of
the indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge
payable in connection with a transfer or exchange.
You
may transfer certificated debt securities and the right to receive the principal of, and premium and interest on, certificated debt securities only by surrendering the old
certificate representing those certificated debt securities and either we or the trustee will reissue the old certificate to the new holder or we or the trustee will issue a new certificate to the new
holder.
Book-Entry Debt Securities
We may issue the debt securities of a series in the form of one or more book-entry debt securities that would be deposited with a
depositary or its nominee identified in the prospectus supplement. We may issue book-entry debt securities in either temporary or permanent form. We will describe in the prospectus supplement the
terms of any depositary arrangement and the rights and limitations of owners of beneficial interests in any book-entry debt security.
8
DESCRIPTION OF WARRANTS
We may issue warrants to purchase debt securities, common stock, preferred stock or other securities or any combination of the
foregoing. We may issue warrants independently or together with other securities. Warrants sold with other securities may be attached to
or separate from the other securities. We will issue warrants under one or more warrant agreements between us and a warrant agent that we will name in the prospectus supplement.
The
prospectus supplement relating to any warrants that we may offer will include specific terms relating to the offering. We will file the form of any warrant agreement with the SEC,
and you should read the warrant agreement for provisions that may be important to you. The prospectus supplement will include some or all of the following
terms:
-
- the title of the warrants;
-
- the aggregate number of warrants offered;
-
- the designation, number and terms of the debt securities, common stock, preferred stock or other securities purchasable upon exercise
of the warrants, and procedures by which those numbers may be adjusted;
-
- the exercise price of the warrants;
-
- the dates or periods during which the warrants are exercisable;
-
- the designation and terms of any securities with which the warrants are issued;
-
- if the warrants are issued as a unit with another security, the date, if any, on and after which the warrants and the other security
will be separately transferable;
-
- if the exercise price is not payable in U.S. dollars, the foreign currency, currency unit or composite currency in which the exercise
price is denominated;
-
- any minimum or maximum amount of warrants that may be exercised at any one time;
-
- any terms, procedures and limitations relating to the transferability, exchange, exercise, amendment or termination of the warrants;
and
-
- any adjustments to the terms of the warrants resulting from the occurrence of certain events or from the entry into or consummation by
us of certain transactions.
DESCRIPTION OF UNITS
As specified in any applicable prospectus supplement, we may issue units consisting of one or more warrants, debt securities, shares of
preferred stock, shares of common stock or any combination of such securities.
DESCRIPTION OF SUBSCRIPTION RIGHTS
As specified in any applicable prospectus supplement, we may issue subscription rights consisting of one or more debt securities,
shares of preferred stock, shares of common stock or any combination of such securities.
PLAN OF DISTRIBUTION
We may sell the securities in one or more of the following ways (or in any combination) from time to
time:
-
- through underwriters or dealers;
9
-
- directly to a limited number of purchasers or to a single purchaser; or
-
- through agents.
Each
time we offer and sell securities under this prospectus, we will file a prospectus supplement. The prospectus supplement will state the terms of the offering of the
securities, including:
-
- the name or names of any underwriters, dealers or agents;
-
- the purchase price of such securities and the proceeds to be received by TetraLogic, if any;
-
- any underwriting discounts or agency fees and other items constituting underwriters' or agents' compensation;
-
- any public offering price;
-
- any discounts or concessions allowed or reallowed or paid to dealers; and
-
- any securities exchanges on which the securities may be listed.
Any
public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.
If
we use underwriters in the sale, the securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions,
including:
-
- negotiated transactions;
-
- at a fixed public offering price or prices, which may be changed;
-
- at market prices prevailing at the time of sale;
-
- at prices related to prevailing market prices; or
-
- at negotiated prices.
Unless
otherwise stated in a prospectus supplement, the obligations of the underwriters to purchase any securities will be conditioned on customary closing conditions and the
underwriters will be obligated to purchase all of such series of securities, if any are purchased.
We
may sell the securities through agents from time to time and may enter into arrangements for "at-the-market" offerings or similar transactions. The prospectus supplement will name any
agent involved in the offer or sale of the securities and any commissions we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment. An agent may
also choose to purchase securities for its own account, as principal.
We
may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from TetraLogic at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in
the prospectus supplement, and the prospectus supplement will set forth any commissions we pay for solicitation of these contracts.
In
offering the shares covered by this prospectus, any broker-dealers and any other participating broker-dealers who execute sales, may be deemed to be "underwriters" within the meaning
of the Securities Act in connection with these sales. Any profits realized by such broker-dealers may be deemed to be underwriting discounts and commissions.
Underwriters
and agents may be entitled under agreements entered into with TetraLogic to indemnification by TetraLogic against certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments which the underwriters or agents may be required to
10
make.
Underwriters and agents may be customers of, engage in transactions with, or perform services for TetraLogic and its affiliates in the ordinary course of business.
Each
series of securities will be a new issue of securities and will have no established trading market other than the common stock which is listed on the NASDAQ Global Market. Any
underwriters to whom securities are sold for public offering and sale may make a market in the securities, but such underwriters will not be obligated to do so and may discontinue any market making at
any time without notice. The securities, other than the common stock, may or may not be listed on a national securities exchange.
The
underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course of their business.
EXPERTS
The financial statements of TetraLogic appearing in TetraLogic's Annual Report (Form 10-K) for the year ended
December 31, 2013 have been audited by Ernst & Young LLP,
independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such financial statements are incorporated herein by
reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.
The
consolidated balance sheets of Shape Pharmaceuticals, Inc. and subsidiary as of December 31, 2013 and 2012, and the related consolidated statements of operations and
comprehensive loss, changes in stockholders' equity (deficiency) and cash flows for each of the years in the three-year period ended December 31, 2013 and for the period from June 11,
2008 (inception) to December 31, 2013 have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated herein by
reference, which report includes an explanatory paragraph about the existence of substantial doubt concerning Shape Pharmaceuticals, Inc. and subsidiary's ability to continue as a going
concern. Such financial statements have been incorporated herein by reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing.
LEGAL MATTERS
Pepper Hamilton LLP will provide us with an opinion as to certain legal matters in connection with the securities being offered
hereby.
11
Shares
PROSPECTUS SUPPLEMENT
Common Stock
William Blair
Nomura
May , 2015
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Aug 2024 to Sep 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Sep 2023 to Sep 2024